Skip to main content
TipRanks
Go Ultimate75% OFF

Ascelia Pharma AB (7ZA) Stock Price & Analysis

2 Followers

7ZA Stock Chart & Stats

€0.04€0.00(12.82%)
At close: 5:30 PM GMT+1
€0.1€0.2Jul 6Jul 20Jul 24Sep 30
Day’s Range
EUR 0.04 - EUR 0.04
52-Week Range
EUR 0.00 - EUR 0.37
Previous Close
EUR 0.04
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 6.97M
Enterprise Value
EUR 78.24M
Total Cash (Recent Filing)
EUR 27.80M
Total Debt (Recent Filing)
EUR 285.00K
Price to Earnings (P/E)
―
Beta
55.11
Next Earnings
Feb 11, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Very low debt reduces refinancing pressure and interest burden while preserving financial flexibility. Compared with a highly leveraged biotech, Ascelia has less obligation to divert future capital toward debt service, leaving more capacity for clinical development and regulatory work if financing remains available.

Narrowing Losses

The substantial reduction in operating losses indicates that spending or operational efficiency has improved from the 2022–2023 peak. Although profitability remains distant, a lower burn rate can extend financial runway and make future funding requirements more manageable as the company advances its lead program.

Focused Oncology Imaging Pipeline

A focused lead product gives Ascelia a clear development and commercialization objective rather than a broad, unfocused pipeline. Orviglance targets liver-metastasis imaging and could address a defined clinical need, creating a pathway to specialized product revenue if approval and adoption are achieved.

Bears Say

No Established Revenue

Ascelia has not yet demonstrated commercial demand or revenue scale, leaving its business model dependent on successful development and approval of Orviglance. Until product sales begin, fixed research and operating costs cannot be absorbed by recurring revenue, keeping execution risk elevated.

Persistent Cash Burn

Consistently negative operating and free cash flow means the company is consuming cash rather than internally funding its programs. This creates continuing dependence on external financing before commercialization, potentially limiting strategic flexibility and exposing development plans to future funding availability.

Eroded Equity Base

The sharp decline in equity reflects the cumulative effect of sustained losses and balance-sheet consumption. A smaller capital base provides less financial resilience for prolonged development timelines, while strongly negative returns show that invested capital is not yet generating economic returns for shareholders.

Ascelia Pharma AB News

7ZA FAQ

What was Ascelia Pharma AB’s price range in the past 12 months?
Ascelia Pharma AB lowest stock price was €0.00 and its highest was €0.37 in the past 12 months.
What is Ascelia Pharma AB’s market cap?
Ascelia Pharma AB’s market cap is €6.97M.
When is Ascelia Pharma AB’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Ascelia Pharma AB’s earnings last quarter?
Ascelia Pharma AB released its earnings results on Nov 05, 2026. The company reported -€0.007 earnings per share for the quarter.
Is Ascelia Pharma AB overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Ascelia Pharma AB pay dividends?
Ascelia Pharma AB does not currently pay dividends.
What is Ascelia Pharma AB’s EPS estimate?
Ascelia Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ascelia Pharma AB have?
Ascelia Pharma AB has 133,535,460 shares outstanding.
What happened to Ascelia Pharma AB’s price movement after its last earnings report?
Ascelia Pharma AB reported an EPS of -€0.007 in its last earnings report. Following the earnings report the stock price went up 10.526%.
Which hedge fund is a major shareholder of Ascelia Pharma AB?
Currently, no hedge funds are holding shares in DE:7ZA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology